| To: Jibacoa who wrote (2777) | 2/7/2012 10:17:37 PM | | From: Jibacoa | of 3185 | | | ARRY was up 7.54% on volume > 4x its ADV.
The stock started an up-trend in mid-December and it hasn't closed the UG it had last month.<g>
bigcharts.marketwatch.com 
ARRY's pipeline includes 4 wholly owned programs and 10 partnered programs, many of which could generate meaningful data in 2012.<g>
Among those is selumetinib (a MEK inhibitor developed with AstraZeneca) for lung Ca.
Selumetinib is also being evaluated in patients with BRAF mutated melanoma and with ocular melanoma.
ARRY also has another MEK inhibitor, (MEK162), which it licensed to to Novartis 2 years ago.
This drug is currently in multiple combination PIs and one PII in melanoma patients with BRAF or NRAS mutations, where is given as monotherapy.
Results are expected at ASCO.
Earlier this month, ARRY announced that the drug achieved clinical proof of concept according to Novartis.<g>
ARRY-520, a KSP inhibitor, is fully owned by ARRY and has already demonstrated signs of efficacy in heavily pre-treated multiple myeloma patients.
The activity seems to be superior to other agents that are now in PIII <g>
ARRY-797 is a p38 inhibitor, which has demonstrated analgesic activity.
It already demonstrated analgesic activity in a dental study reported in 2008 as well as in a trial in rheumatoid arthritis.
ARRY recently initiated a randomized trial in patients with osteoarthritis of the knee, where the drug is compared head to head with an opioid or placebo.
The goal is proving that ARRY-797 is at least as effective as the opioid analgesic, with the intent of replacing opioids that are associated with side effects and addiction issues.
Results are expected later this year.
The ACTAY is $4
The stock has a good amount of resistance at that level.
But with some good reports, the stock could get to test the $6 level.<g>
bigcharts.marketwatch.com
Bernard
|
| | Biotech & Pharma.T.A, | Stock Discussion ForumsShare | Recommend | Keep | Reply | Mark as Last Read |
|
